Rpc, Inc.
—- Market cap
- —
- Debt
- +$20.00M
- Cash
- −$209.97M
Complete market value, debt and cash evidence is required for enterprise value.
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: RES stock price vs AMRN: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at AMRN's multiple
Needs AMRN P/E.
Implied fair value · at RES's multiple
Needs Annual EPS is negative, RES P/E.
Metric by metric
Where each company leads, and how wide the gap is.
Price unavailable
Growth edge
Pricing power
Operating leverage
Lower is better
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: RES FY 2025 (ended Dec 31, 2025) · AMRN FY 2025 (ended Dec 31, 2025).
Trendline
Eight period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
Market cap plus debt, less cash.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
RPC, INC. · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
AMARIN CORP PLC\UK · implied price per share
Five annual free-cash-flow observations are required for the filing-backed baseline.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Debt / equity
Total debt against shareholders' equity
0.02x
0.39x
Net debt / EBITDA
Leverage against operating earnings
-0.87x
3.79x
Cash and equivalents
Liquid reserves on the balance sheet
$209.97M
$302.59M
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
NABORS INDUSTRIES LTD
RES vs NBR
Helmerich & Payne, Inc.
RES vs HP
TETRA TECHNOLOGIES INC
RES vs TTI
LIGAND PHARMACEUTICALS INC
RES vs LGND
Harmony Biosciences Holdings, Inc.
RES vs HRMY
SUPERNUS PHARMACEUTICALS, INC.
RES vs SUPN
Viatris Inc
RES vs VTRS
Organon & Co.
RES vs OGN
INCYTE CORP
RES vs INCY
$20.00M
$177.39M
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.